Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 601–700 of 1,001
Roth, S., Apte, M. V., Balachandran, V. P., Biffi, G., Conroy, T., Cukierman, E., Dotan, E., Esposito, I., Grünwald, B. T., Klauß, M., et al. (2026) · Nature Reviews Disease Primers · doi:10.1038/s41572-026-00699-6 · Cited by 28
Self-citationLocal Destruction of Tumors and Systemic Immune Effects
Tranberg, K. ‐. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708810 · Cited by 17
Eckhoff, A. M., Fletcher, A. A., Landa, K., Iyer, M. K., Nussbaum, D. P., Shi, C., Nair, S. K., & Allen, P. J. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12157-0 · Cited by 18
Self-citationThe Effects of Clonal Heterogeneity on Cancer Immunosurveillance
Dijkstra, K. K., Wu, Y., & Swanton, C. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-101910 · Cited by 17
Qian, J., Zhang, X., Wei, B., Tang, Z., & Zhang, B. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188943 · Cited by 17
Cohn, D. E., Forder, A., Marshall, E. A., Vucic, E. A., Stewart, G. L., Noureddine, K., Lockwood, W. W., MacAulay, C. E., Guillaud, M. D., & Lam, W. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275890 · Cited by 20
Luo, B., An, Q., Lei, J., Tan, D., Liu, X., Li, H., Zhao, Y., Qin, J., Zhang, C., Zhang, Y., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2447821 · Cited by 21
Oyama, K., Nakata, K., Abe, T., Hirotaka, K., Fujimori, N., Kiyotani, K., Iwamoto, C., Ikenaga, N., Morisaki, S., Umebayashi, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571182 · Cited by 16
Gómez-Rubio, P., Piñero, J., Molina‐Montes, E., Gutiérrez‐Sacristán, A., Márquez, M., Rava, M., Michalski, C. W., Farré, A., Molero, X., Löhr, M. J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31866 · Cited by 17
McKenzie, N. D., Hong, H. S., Ahmad, S., & Holloway, R. W. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103165 · Cited by 16
Alzhrani, R. M., Alsaab, H. O., Vanamala, K., Bhise, K., Tatiparti, K., Barari, A., Sau, S., & Iyer, A. K. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000262 · Cited by 18
Xu, P., Li, C., Xi, S., Chen, F., Wang, J., Zhang, Z., Liu, Y., Li, X., & Chen, Z. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.034 · Cited by 18
Research into the characteristic molecules significantly affecting liver cancer immunotherapy
Chen, J., Jin, H., Zhou, H., Hei, X., & Liu, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1029427 · Cited by 20
Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer
Yan, X.-D., Bai, L., Qi, P., Lv, J., Song, X., & Zhang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411387 · Cited by 16
Intrinsic Properties of the Lymph Node Render It Immunologically Susceptible to Metastasis
Kahn, B., Ng, R. W. S., Kim, I., Eskandarian, C., Chen, C. O., Huang, B., Lucas, A., Li, L., Maillard, I. P., & Stanger, B. Z. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1847 · Cited by 16
Neoantigen-Based Immunotherapy in Lung Cancer: Advances, Challenges and Prospects
Li, X., Zhu, Y., Xue, Y., Chen, T., Sun, X., & Shi, H. (2025) · Cancers · doi:10.3390/cancers17121953 · Cited by 18
Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity
Hernandez, R., & Malek, T. R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.878377 · Cited by 18
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 18
Dickerson, L. K., Carter, J. A., Kohli, K., & Pillarisetty, V. G. (2023) · Gut · doi:10.1136/gutjnl-2023-329650 · Cited by 19
Ashina, S., Masuda, A., Yamakawa, K., Hamada, T., Tsujimae, M., Tanaka, T., Toyama, H., Sofue, K., Shiomi, H., Sakai, A., et al. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02020-8 · Cited by 15
Jiang, Y., Ye, Y., Huang, Y., Wu, Y., Wang, G., Gui, Z., Zhang, M., & Zhang, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05285-x · Cited by 17
Decoding the obesity–cancer connection: lessons from preclinical models of pancreatic adenocarcinoma
Ruiz, C. F., Garcia, C. C., Jacox, J. B., Lawres, L., & Muzumdar, M. D. (2023) · Life Science Alliance · doi:10.26508/lsa.202302228 · Cited by 17
Emerging Prognostic and Predictive Factors in Pancreatic Cancer
Karamitopoulou, E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100328 · Cited by 17
Tsunedomi, R., Shindo, Y., Nakajima, M., Yoshimura, K., & Nagano, H. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2281482 · Cited by 15
Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma
Singh, G., Kutcher, D., Lally, R., & Rai, V. (2024) · Cancers · doi:10.3390/cancers16112101 · Cited by 17
Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes
Tokita, S., Fusagawa, M., Matsumoto, S., Mariya, T., Umemoto, M., Hirohashi, Y., Hata, F., Saito, T., Kanaseki, T., & Torigoe, T. (2024) · Science Advances · doi:10.1126/sciadv.ado6491 · Cited by 19
Macfarlane, F. R., Chaplain, M. A. J., & Lorenzi, T. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.07.019 · Cited by 17
Context-Dependent Immune Responses Explain Pancreatic Cancer Immunoresistance
Bednar, F., & di Magliano, M. P. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.02.010 · Cited by 16
Tan, H. N., Catedral, L. I. G., & Juan, M. D. S. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000331 · Cited by 17
Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer
Yu, Y., Schuck, K., Frieß, H., & Kong, B. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1857727 · Cited by 18
Yılmaz, H., Toy, H. I., Marquardt, S., Karakülah, G., Küçük, C., Kontou, P. I., Logotheti, S., & Pavlopoulou, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179601 · Cited by 16
Solving the puzzle of what makes immunotherapies work
Ma, X., & Chan, T. A.-T. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.011 · Cited by 15
Self-citationMeng, Q., Valentini, D., Rao, M., Dodoo, E., & Maeurer, M. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-34710-2 · Cited by 16
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment
Arnold, F., Vecchio, A. D., Hussain, Z., & Sherman, M. H. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-025-00905-9 · Cited by 17
Kisling, S. G., Atri, P., Shah, A., Cox, J. L., Sharma, S., Smith, L. M., Ghersi, D., & Batra, S. K. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0825 · Cited by 15
Smith, H., Arbe-Barnes, E. H., Abu‐Shah, E., & Sivakumar, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1406250 · Cited by 15
Schmidt, M., & Lill, J. R. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.021 · Cited by 15
Besneux, M., Greenshields‐Watson, A., Scurr, M. J., MacLachlan, B. J., Christian, A. D., Davies, M. M., Hargest, R., Phillips, S. M., Godkin, A. J., & Gallimore, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2266-1 · Cited by 17
T Cell Receptor Engineered Lymphocytes for Cancer Therapy
Rollins, M. R., Spartz, E. J., & Stromnes, I. M. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.97 · Cited by 16
Shinkawa, T., Tokita, S., Nakatsugawa, M., Kikuchi, Y., Kanaseki, T., & Torigoe, T. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1870062 · Cited by 17
Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC
Cattolico, C., Bailey, P., & Barry, S. T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.816517 · Cited by 18
Emerging Biomarkers for Immunotherapy in Glioblastoma
Mensali, N., & Inderberg, E. M. (2022) · Cancers · doi:10.3390/cancers14081940 · Cited by 17
Agostini, A., Orlacchio, A., Carbone, C., & Guerriero, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876291 · Cited by 15
Fujiwara, K., Shao, Y., Niu, N., Zhang, T., Herbst, B. T., Henderson, M., Muth, S. T., Zhang, P., & Zheng, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01373-6 · Cited by 17
Self-citationEpigenetic modulation enhances immunotherapy for pancreatic ductal adenocarcinoma
Li, Y., Hong, Y. K., Wang, X., Pandit, H., Zheng, Q., Yu, Y., Shi, X., Chen, Y., Tan, M., Pulliam, Z., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1430 · Cited by 14
Lee, B., Hutchinson, R. A., Wong, H., Tie, J., Putoczki, T. L., Tran, B., Gibbs, P., & Christie, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.009 · Cited by 18
Ho, J., Li, X., Zhang, L., Liang, Y., Hu, W., Yau, J. C. W., Chan, H., Gin, T., Chan, M. T. V., Tse, G., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.004 · Cited by 15
Nonomura, C., Otsuka, M., Kondou, R., Iizuka, A., Miyata, H., Ashizawa, T., Sakura, N., Yoshikawa, S., Kiyohara, Y., Ohshima, K., et al. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.02.004 · Cited by 14
Lupo, F., Piro, G., Torroni, L., Delfino, P., Trovato, R., Rusev, B. C., Fiore, A., Filippini, D., Sanctis, F. D., Manfredi, M., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00308 · Cited by 15
The Clinical Application of Neoantigens in Esophageal Cancer
Gu, Y., Zhuo, Y., Chen, L., & Yuan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703517 · Cited by 15
Malchiodi, Z. X., Cao, H., Gay, M. D., Safronenka, A., Bansal, S., Tucker, R. D., Weinberg, B. A., Cheema, A. K., Shivapurkar, N., & Smith, J. P. (2021) · Cancers · doi:10.3390/cancers13194949 · Cited by 15
Targeting Neoantigens for Personalised Immunotherapy
Pritchard, A. L. (2018) · BioDrugs · doi:10.1007/s40259-018-0267-4 · Cited by 14
Is Immunotherapy the Holy Grail for Pancreatic Cancer?
Andersson, R. E., Pereira, C., Bauden, M. P., & Ansari, D. (2019) · Immunotherapy · doi:10.2217/imt-2019-0164 · Cited by 14
Dudgeon, C., Harris, C. R., Chen, Y., Ghaddar, B., Sharma, A., Shah, M. M., Roberts, A. I., Casabianca, A., Collisson, E. A., Balachandran, V. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.13.037374 · Cited by 16
Self-citationThe Landmark Series: Therapeutic Cancer Vaccine Strategies for Cold Tumors
Blair, A. B., Zheng, L., & Soares, K. C. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17281-1 · Cited by 13
Zhang, P., Pan, J., Lin, S., Peng, B., Zhang, J., Zhang, J., Xu, L., Lai, Y. L., Yu, H., & Xu, Z. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115620 · Cited by 15
Self-citationZhou, S., Liang, Y., Hao, Y., Wang, Q., Xu, Y., Su, T., Cheng, F., & Zhu, G. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102623 · Cited by 15
Advances in mRNA‐Lipid Nanoparticle Engineering for Immune Cell Targeting and Immune Modulation
Kim, C., Lee, Y., Lee, H., & Kim, B. (2025) · Small Methods · doi:10.1002/smtd.202501401 · Cited by 14
Yu, J., Wang, L., Kong, X., Cao, Y., Zhang, M., Sun, Z., Liu, Y., Wang, J., Shen, B., Bo, X., et al. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.819583 · Cited by 14
Antigenic molecular mimicry in viral-mediated protection from cancer: the HIV case
Manolio, C., Ragone, C., Cavalluzzo, B., Mauriello, A., Tornesello, M. L., Buonaguro, L., Megna, M., D’Alessio, G., Penta, R., Tagliamonte, M., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03681-4 · Cited by 14
Zhao, Z., Lin, Z., Guo, X., Al-Danakh, A., He, H., Qin, H., Ma, C., Zhang, N., & Tan, G. (2023) · Journal of Immunology Research · doi:10.1155/2023/4311388 · Cited by 15
Historical perspective and future directions: computational science in immuno-oncology
Ricker, C. A., Meli, K., & Allen, E. M. V. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008306 · Cited by 15
Advancements in Preclinical Models of Pancreatic Cancer
Salu, P., & Reindl, K. M. (2024) · Pancreas · doi:10.1097/mpa.0000000000002277 · Cited by 15
Clinical Evaluation of the Pancreatic Cancer Microenvironment: Opportunities and Challenges
Szczepanski, J. M., Rudolf, M. A., & Shi, J. (2024) · Cancers · doi:10.3390/cancers16040794 · Cited by 18
Zhang, H., Xu, W., Zhu, H., Chen, X., & Tsai, H. (2024) · Journal of Cancer · doi:10.7150/jca.92502 · Cited by 14
Zhao, Y., Qin, C., Chen, L., Li, Z., Zhao, B., Li, T., Zhang, X., & Wang, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189183 · Cited by 16
KRASG12D drives immunosuppression in lung adenocarcinoma through paracrine signaling
Opsahl, E. L. L., Barravecchia, I., McLintock, E., Lee, J. M., Ferris, S. F., Espinoza, C. E., Hinshaw, R., Cavanaugh, S., Robotti, M., Rober, L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.182228 · Cited by 16
Immunomodulation in Pancreatic Cancer
Krishnamoorthy, M., Lenehan, J. G., Burton, J. P., & Vareki, S. M. (2020) · Cancers · doi:10.3390/cancers12113340 · Cited by 15
Kumar, P., Boyne, C., Brown, S., Qureshi, A. A., Thorpe, P., Synowsky, S. A., Shirran, S. L., & Powis, S. J. (2022) · Immunology · doi:10.1111/imm.13471 · Cited by 14
Antibody-Based Approaches to Target Pancreatic Tumours
Sorbara, M., Cordelier, P., & Béry, N. (2022) · Antibodies · doi:10.3390/antib11030047 · Cited by 17
Harnessing the Microbiome to Reduce Pancreatic Cancer Burden
Bastos, A. R., Pereira‐Marques, J., Ferreira, R. M., & Figueiredo, C. (2023) · Cancers · doi:10.3390/cancers15092629 · Cited by 15
Bowers, J. S., Bailey, S. R., Rubinstein, M. P., Paulos, C. M., & Camp, E. R. (2019) · Oncology Reviews · doi:10.4081/oncol.2019.430 · Cited by 14
Microbes as Master Immunomodulators: Immunopathology, Cancer and Personalized Immunotherapies
Lérias, J. R., Paraschoudi, G., de Sousa, E., Martins, J. D., Condeço, C., Figueiredo, N., Carvalho, C. T., Dodoo, E., Castillo-Martín, M., López-Beltrán, A., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00362 · Cited by 14
Stifter, K., Dekhtiarenko, I., Krieger, J., Tissot, A. C., Seufferlein, T. T. W., Wagner, M., & Schirmbeck, R. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.04.003 · Cited by 13
The Unique Microbiome and Immunity in Pancreatic Cancer
Wei, X., Mei, C., Li, X., & Xie, Y. (2021) · Pancreas · doi:10.1097/mpa.0000000000001744 · Cited by 14
Shi, R., Li, Y., Ran, L., Dong, Y., Zhou, X., Tang, J., Han, L., Wang, M., Pang, L., Qi, Y., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1944-5 · Cited by 13
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Microbiome modulation of antigen presentation in tolerance and inflammation
He, Y., Mohapatra, G., Asokan, S., Nobs, S. P., & Elinav, E. (2024) · Current Opinion in Immunology · doi:10.1016/j.coi.2024.102471 · Cited by 13
The Past, Present, and Future of Biomarkers for the Early Diagnosis of Pancreatic Cancer
Vitale, F., Verme, L. Z. D., Paratore, M., Negri, M., Nista, E. C., Ainora, M. E., Esposto, G., Mignini, I., Borriello, R., Galasso, L., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122840 · Cited by 16
Gut Microbiome and the Response to Immunotherapy in Cancer
Stancu, A. L. (2018) · Discoveries · doi:10.15190/d.2018.4 · Cited by 14
Neoantigens and NK Cells: “Trick or Treat” the Cancers?
Lv, D., Khawar, M. B., Liang, Z., Gao, Y. M., & Sun, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931862 · Cited by 12
Moser, R. D., Annis, J. E., Nikolova, O. H., Whatcott, C., Gurley, K. E., Méndez, E., Moran‐Jones, K., Dorrell, C., Sears, R. C., Kuo, C. J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4222 · Cited by 12
Wang, C., Chen, Y., Yin, X., Xu, R., Song, J., Ruze, R., Xu, Q., & Zhao, Y. (2022) · BMC Cancer · doi:10.1186/s12885-022-09927-0 · Cited by 14
Liu, Q., Zhao, H., Guo, Y. L., Zhang, K., Shang, F., & Liu, T. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/7904982 · Cited by 14
Jainarayanan, A., Anand, N. M., Arbe-Barnes, E. H., Bush, A. J., Bashford-Rogers, R. J. M., Frampton, A. E., Heij, L. R., Middleton, M. R., Dustin, M. L., Abu‐Shah, E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106324 · Cited by 12
Wang, R., Zhang, J., Cui, X. L., Wang, S. L., Chen, T., Niu, Y., Du, X., Kong, J., Wang, L., & Jiang, Y. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02877-8 · Cited by 14
Self-citationrWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses
Ye, J., Wang, H., Medina, R., Chakraborty, S., Sun, M., Valenzuela, A., Sang, X., Zhang, Y., Uher, O., Ženka, J., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02744-8 · Cited by 13
Impact of Neoantigen Expression and T-Cell Activation on Breast Cancer Survival
Li, W., Amei, A., Bui, F., Norouzifar, S., Lu, L., & Wang, Z. (2021) · Cancers · doi:10.3390/cancers13122879 · Cited by 13
Yang, H., Yu, M. Y., Zhong, S., You, Y., & Feng, F. (2022) · Journal of Ovarian Research · doi:10.1186/s13048-022-00955-9 · Cited by 12
Chung, W., Chu, M.-T., Hou, M., Lee, Y., Yang, C., Chu, S., Liu, F., Hsu, H., Pao, S.-C., Teng, Y.-C., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115928 · Cited by 12
Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy
Minegishi, Y., Haga, Y., & Ueda, K. (2024) · Cancer Science · doi:10.1111/cas.16118 · Cited by 12
Freeman, P., Bellomo, G., Ireland, L., Abudula, M., Luckett, T., Oberst, M. D., Stafferton, R., Ghaneh, P., Halloran, C. M., Schmid, M. C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1382538 · Cited by 13
Splicing dysregulation: hallmark and therapeutic opportunity in pancreatic cancer
Naro, C., Ruta, V., & Sette, C. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.11.007 · Cited by 14
Cai, Z., Li, Z., Zhong, W., Lin, F., Dong, X., Ye, H., Guo, Y., Chen, G., Yu, X., Yu, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202407976 · Cited by 13
Xu, Y., Wang, B., Huang, Y., Liao, J., Wu, C., Zhou, C., Kang, Z., Jiang, S., Wu, B., Zhang, D., et al. (2025) · Advanced Science · doi:10.1002/advs.202500021 · Cited by 20
Primary and metastatic cellular landscapes in human pancreatic cancer
Steele, N. G., Sirihorachai, V. R., Elhossiny, A. M., Loveless, I. M., Kadiyala, P., Bonilla, M. E., Opsahl, E. L. L., Vargas, C. S., Donahue, K. L., Kemp, S. B., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113012 · Cited by 12
Drug Repurposing by Tumor Tissue Editing
Lüke, F., Harrer, D. C., Pantziarka, P., Pukrop, T., Ghibelli, L., Gerner, C., Reichle, A., & Heudobler, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.900985 · Cited by 11
Shen, Y., Yu, L., Xu, X., Yu, S., & Yu, Z. (2022) · Cancer Innovation · doi:10.1002/cai2.26 · Cited by 13
Li, L., Wang, J., Zhang, Z., Yang, Q., Deng, Z., Zou, W., Ge, X., Pan, K., Li, C., & Liu, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1052768 · Cited by 14
Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD
Chen, M., Zhang, X., Ming, Z., Lingyu, Feng, X., Han, Z., & An, H. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05103-z · Cited by 11
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.